Interestingly, inhibitors of HDACs, such as suberoylanilide hydroxamic acid (SAHA) [72], trichostatin A (TSA) [54], phenylbutyrate [73], sodium butyrate [74], valproic acid [75], and hydroxyurea increase SMN2 full length transcript and have been demonstrated to ameliorate SMA phenotype at least in mouse models [76,77]. Here, SMN2 is linked to proximal spinal muscular atrophy.